by Galecto Inc. Appoints Stephanie Oestreich As Chief Business Officer
Publicly-traded biotech company Galecto Inc. recently announced the appointment of Stephanie Oestreich as its Chief Business Officer. Oestreich brings a wealth of experience in biotechnology and pharmaceuticals to her new position. The company focuses on developing novel cancer and fibrosis treatments and has recently announced its operating results for the quarter ended September 30, 2021. Stephanie Oestreich’s background in biotechnology, pharmaceuticals, and healthcare has proven beneficial for Galecto.
Galecto Biotech
Galecto Biotech Inc. is a biotech firm that focuses on developing small molecules to treat inflammation and severe diseases, including cancer. Galecto Inc company was founded in 2011 by leading researchers in the field of galectins and biotech executives from the United Kingdom, Sweden, and Denmark. This group of researchers has a history of developing small molecules that have been used to treat cancer and other serious diseases. Although it is still in its early stage, the company has already made impressive progress.
The company has a history of developing small molecules and is committed to developing innovative products to treat inflammation and serious diseases. The company was founded in 2011 by several leading biotech executives and scientists in Sweden and Denmark. The company has over 25 employees and is currently incorporated in the U.S. Galecto’s focus is on the therapeutic potential of galectin-3 modulators for inflammatory diseases and cancer. The company also has an impressive patent estate and a promising therapeutic platform.
The company is also advancing its lead drug candidate, GB0139, through a phase IIb trial. The funding will also help the company move two other programs through phase II. The drug is designed to help treat a broad range of fibrotic diseases. The company is developing GB0139 to treat severe lung conditions. The drug is being tested on people with idiopathic pulmonary fibrosis.
GB0139
A biotechnology company focused on developing new treatments for cancer and fibrosis has announced the reopening of enrollment for its Phase 2b GALACTIC-1 study of GB0139 for IPF. This study is now accepting new patients from Belgium and areas affected by the recent coronavirus. GB0139 is an inhaled small molecule inhibitor of Galectin-3, a protein central to fibrosis in several organs.
The company’s pipeline includes multiple product candidates for severe fibrotic diseases. Among these, GB0139 is an inhaled galectin-3 modulator being developed for idiopathic pulmonary fibrosis. Although Galecto is currently only in the Phase 2b stage of its research program, it has high hopes of achieving the ultimate goal of providing patients with a life-altering treatment for their fibrotic condition.
The GB0139 trial is a randomized, placebo-controlled phase 2b study in patients with advanced IPF. The study is designed to evaluate the safety and efficacy of the galectin-3 inhibitor compared with placebo. The drug is being studied as a once-daily inhalation. This study is expected to measure time to first hospitalization for 450 patients with idiopathic pulmonary fibrosis.
GB1211 combination with Roche’s atezolizumab
Galecto, Inc. is a biotechnology company focused on developing novel cancer and fibrosis treatments. It recently announced the first patient enrollment in a Phase 2a trial for its oral galectin-3 inhibitor GB1211, and Roche’s PD-L1 checkpoint inhibitor atezolizumab. The drug combination is intended to target tumors by inhibiting the Galectin-3 pathway, which is thought to drive cancer growth.
GB1211 is a small molecular inhibitor of galectin-3. It is administered twice daily in combination with atezolizumab. The study is expected to collect long-term safety and efficacy data from patients. Its safety profile is similar to that of atezolizumab. It is expected to show clinical activity in a combination of atezolizumab, but it is not a cure for fibrosis.
The combination will be studied in patients with advanced NSCLC that demonstrate measurable disease per RECIST v1.1 and expresses programmed death ligand-1 on more than 50% of tumor cells. Patients must not have untreated central nervous system metastases or previously undergone systemic chemotherapy. Patients must also not have a prior EGFR mutation. Patients must also wait four weeks before starting GB1211.
